BioSpace News Archive

Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.

Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.

Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.

Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.

There have already been several big biotech licensing deals in Q1. See inside for some of this quarter’s biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.

Aural Analytics, Inc.today announced that its Speech Vitals - ALS technology has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA).

Wugen, Inc. today announced an upcoming presentation highlighting WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product.

The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc., Microsoft, Twist Bioscience Corporation and Western Digital to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.

BioCardia®, Inc. today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.

Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced that it has received approval from Health Canada to import Eptifibatide solution for infusion and injection (“Eptifibatide”) pursuant to Health Canada’s exceptional importation and sale guidelines.